WVE - CIK 0001631574
Wave Life Sciences Ltd. trades as WVE and has a market capitalization of $1.09 B, making it the #2576 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $42.73M, down 60.5% from the prior year and net income of -$204.38M. This page tracks Wave Life Sciences Ltd. through 695 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years Wave Life Sciences Ltd.'s revenue grew from $1.09M to $42.73M, a compound annual growth rate of 50.3%. Net profit margin expanded from -5097.1% to -478.3% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-18 |
| SCHEDULE 13G/A | - | 2026-05-13 |
| Proxy statement | DEF 14A | 2026-05-07 |
| SCHEDULE 13G/A | - | 2026-05-06 |
| PRER14A | - | 2026-05-01 |
| Annual report (amended) | 10-K/A | 2026-04-30 |
| Quarterly report | 10-Q | 2026-04-28 |
| Major company event | 8-K | 2026-04-28 |
Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update - Wave Life Sciences
Wave Life Sciences Announces Proposed Redomiciliation to the United States - Wave Life Sciences
Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Wave Life Sciences
The largest companies sharing Wave Life Sciences Ltd.'s SEC industry classification (pharmaceutical preparations).
Wave Life Sciences Ltd. (WVE) has a market capitalization of $1.09 B as of 2026-06-10, ranking #2576 among US-listed companies.
Wave Life Sciences Ltd. reported revenue of $42.73M for fiscal year 2025, a decrease of 60.5% year over year.
In its latest fiscal year Wave Life Sciences Ltd. reported a net loss of $204.38M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.